Last checked at 29 Mar 2021 16:00
MyHealthChecked plc
("MyHealthChecked" or "the Company")
Further COVID-19 Government testing approvals
MyHealthChecked approved as a PCR and sequencing provider
for day two and day eight coronavirus testing for international arrivals
MyHealthChecked plc (AIM: MHC), the consumer home-testing healthcare company, announces that, under the name of its subsidiary Concepta Diagnostics, it has been added to the UK Government's approved list as a private provider of day two and day eight ('D2/D8') coronavirus testing for all international arrivals1 for both SARS-CoV-2 PCR testing and SARS-CoV-2 genome sequencing testing services.
This follows confirmation notified on 29 December 2020 that MyHealthChecked had been added to the UK Government's approved COVID-19 private testing list for General Testing and the Test to Release for International Travel schemes.
The COVID-19 testing services provided by MyHealthChecked meet the Department of Health and Social Care's ('DHSC') 15 minimum standards2 and have been reviewed by UKAS, a national accreditation body recognised by the UK Government to assess against international agreed standards. From 15 February 2021, international arrivals are required to self-isolate for 10 days on return to the UK and take a polymerase chain reaction ('PCR') test on day two and day eight of the passenger's quarantine period. If the day two test result is positive and meets the DHSC sequencing criteria, it requires sequencing in a lab for surveillance purposes to monitor Variants of Concern and Variants Under Investigation, which is reported directly back to Public Health England. PCR testing can be undertaken in the Company's own laboratory or that of Yourgene Health plc, and in the case of positive day 2 COVID-19 results, sequencing will be undertaken at the laboratories of Yourgene Health plc.
MyHealthChecked will be adding the D2/D8 service to its current COVID-19 services in early April, from when tests can be ordered directly from the website: https://myhealthchecked.com/
Penny McCormick, CEO of MyHealthChecked commented: "This is another positive step for MyHealthChecked and a further demonstration of our versatility as a company. We are pleased to be supporting the COVID-19 testing efforts as the possibility of travel may increase and we are all hopeful of a degree of normality returning in the coming weeks. Approval from the DHSC only further confirms the competency of our testing services, putting MyHealthChecked in an incredibly competitive position in the market."
1 - https://www.gov.uk/guidance/providers-of-day-2-and-day-8-coronavirus-testing-for-international-arrivals#book-a-travel-test-package
2 - https://www.gov.uk/government/publications/testing-to-release-for-international-travel-minimum-standards-for-testing/minimum-standards-for-private-sector-providers-of-covid-19-testing-for-testing-to-release-for-international-travel
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.
For further information please contact:
MyHealthChecked plc | www.myhealthcheckedplc.com |
Penny McCormick, Chief Executive Officer | via Walbrook PR |
Maddy Kennedy, Chief Financial Officer | |
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 |
Neil Baldwin | |
Oberon Investments (Broker) | Tel: +44 (0)203 179 5344 |
Mike Seabrook | mikeseabrook@oberoninvestments.com |
Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or myhealthchecked@walbrookpr.com |
Paul McManus | Mob: +44(0)7980 541 893 |
Alice Woodings | Mob: +44(0)7407 804 654 |
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company with two diverse, customer-facing at-home testing brands in its portfolio:
MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the recent acquisition of The Genome Store. The tests will be made available on line, and would be viable for over the counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.
Mylo targets the personalized mobile health market, with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant, by enabling her to quantitively track her levels of luteinizing hormone (LH) prior to ovulation.